---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061519"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:34:32.855632+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients

## Summary
- Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.
- IK-930 dose escalation: 26 patients treated; 7/7 EHE patients achieved stable disease, 3 with tumor shrinkage.
- Treatment-related proteinuria in 3/26 patients, all grade 1-2, no dose reductions or interruptions.
- IK-595 clinical trial expected to initiate by end of 2023; IK-930 data update planned for H2 2024.
- Collaboration revenue $1.2M vs $6.4M YoY; R&D expenses $14.7M vs $18.9M YoY.

## SEC filing metadata
- accession: 0000950170-23-061519
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/0000950170-23-061519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/ikna-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061519
- JSON: https://secwatch.observer/filing/0000950170-23-061519.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061519.txt

## Key facts
- Earnings Releases
  ImageneBio, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Ikena Oncology, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000095017023061519/0000950170-23-061519-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.